文献速递胸部肿瘤放疗放疗物理与技术

多组学信息整合的深度学习架构用于Ⅲ期非小细胞肺癌放疗后联合预测

Integrating Multiomics Information in Deep Learning Architectures for Joint Actuarial Outcome Prediction in Non-Small Cell Lung Cancer Patients After Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-01

该研究提出精算深度学习神经网络(ADNN)架构,用于Ⅲ期非小细胞肺癌(NSCLC)患者放疗后放射性肺炎(RP)和局部控制(LC)的联合预测。模型整合PET影像组学、细胞因子和miRNA等多组学信息,并在117例回顾性患者中评估、25例前瞻性患者中独立测试、327例RTOG0617数据集中外部验证。ADNN-com-joint对RP2和LC的联合预测c-index分别为0.705和0.740,AU-FROC为0.729,优于传统NTCP/TCP模型。

要点

  • 多组学整合的ADNN模型在RP2和LC预测上优于传统NTCP/TCP模型。
  • ADNN-com-joint实现RP2与LC联合预测,c-index分别为0.705和0.740。
  • 外部验证采用RTOG0617数据集327例患者,结果与内部测试相似。

核心结论

  • 整合多组学信息的深度学习架构在RP2和LC的精算预测中优于传统NTCP/TCP模型。

研究设计与样本

  • 研究提出三种ADNN架构:ADNN-DVH仅用剂量学信息,ADNN-com整合多组学信息,ADNN-com-joint联合预测RP2和LC。
  • 模型在117例回顾性患者中评估,25例新入组患者前瞻性独立测试,327例RTOG0617多机构数据集外部验证。

主要发现

  • ADNN-DVH交叉验证c-index:RP2为0.660(95%CI 0.630-0.690),LC为0.727(95%CI 0.700-0.753),优于广义Lyman模型(RP2 0.613 [0.583-0.643])和广义log-logistic模型(LC 0.569 [0.545-0.594])。
  • ADNN-com在交叉验证和独立内部测试中均优于ADNN-DVH。
  • ADNN-com-joint联合预测c-index:RP2为0.705(95%CI 0.676-0.734),LC为0.740(95%CI 0.714-0.765),AU-FROC为0.729(95%CI 0.697-0.773)。

临床怎么用

  • 该模型可用于Ⅲ期NSCLC患者放疗后RP2和LC的精算预测,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Novel actuarial deep learning neural network (ADNN) architectures are proposed for joint prediction of radiation therapy outcomes-radiation pneumonitis (RP) and local control (LC)-in stage III non-small cell lung cancer (NSCLC) patients. Unlike normal tissue complication probability/tumor control probability models that use dosimetric information solely, our proposed models consider complex interactions among multiomics information including positron emission tomography (PET) radiomics, cytokines, and miRNAs. Additional time-to-event information is also used in the actuarial prediction. METHODS AND MATERIALS: Three architectures were investigated: ADNN-DVH considered dosimetric information only; ADNN-com integrated multiomics information; and ADNN-com-joint combined RP2 (RP grade ≥2) and LC prediction. In these architectures, differential dose-volume histograms (DVHs) were fed into 1D convolutional neural networks (CNN) for extracting reduced representations. Variational encoders were used to learn representations of imaging and biological data. Reduced representations were fed into Surv-Nets to predict time-to-event probabilities for RP2 and LC independently and jointly by incorporating time information into designated loss functions. RESULTS: Models were evaluated on 117 retrospective patients and were independently tested on 25 newly accrued patients prospectively. A multi-institutional RTOG0617 data set of 327 patients was used for external validation. ADNN-DVH yielded cross-validated c-indexes (95% confidence intervals) of 0.660 (0.630-0.690) for RP2 prediction and 0.727 (0.700-0.753) for LC prediction, outperforming a generalized Lyman model for RP2 (0.613 [0.583-0.643]) and a generalized log-logistic model for LC (0.569 [0.545-0.594]). The independent internal test and external validation yielded similar results. ADNN-com achieved an even better performance than ADNN-DVH on both cross-validation and independent internal test. Furthermore, ADNN-com-joint, which yielded performance similar to ADNN-com, realized joint prediction with c-indexes of 0.705 (0.676-0.734) for RP2 and 0.740 (0.714-0.765) for LC and achieved an area under a free-response receiving operator characteristic curve (AU-FROC) of 0.729 (0.697-0.773) for the joint prediction of RP2 and LC. CONCLUSION: Novel deep learning architectures that integrate multiomics information outperformed traditional normal tissue complication probability/tumor control probability models in actuarial prediction of RP2 and LC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Cui S, Ten Haken RK, El Naqa I, et al. Integrating Multiomics Information in Deep Learning Architectures for Joint Actuarial Outcome Prediction in Non-Small Cell Lung Cancer Patients After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33539966. doi:10.1016/j.ijrobp.2021.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。